Saad Mark E 4
4 · Axsome Therapeutics, Inc. · Filed Jan 2, 2026
Insider Transaction Report
Form 4
Saad Mark E
Director
Transactions
- Exercise/Conversion
Common Stock
2025-12-31$8.02/sh+6,231$49,973→ 16,233 total - Sale
Common Stock
2025-12-31$165.18/sh−6,231$1,029,237→ 10,002 total - Exercise/Conversion
Common Stock
2025-12-31$4.95/sh+31,346$155,163→ 41,348 total - Sale
Common Stock
2025-12-31$165.18/sh−31,346$5,177,732→ 10,002 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-31−6,231→ 0 totalExercise: $8.02From: 2017-05-27Exp: 2026-05-27→ Common Stock (6,231 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-31−31,346→ 0 totalExercise: $4.95From: 2018-03-15Exp: 2027-03-15→ Common Stock (31,346 underlying)
Holdings
- 300(indirect: See explanation 5 below.)
Common Stock
Footnotes (5)
- [F1]Represents an exercise of stock options prior to the 10-year expiration date of such options.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
- [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $165.00 and $166.09.
- [F5]Represents additional shares held indirectly by the Reporting Person prior to December 31, 2025 which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.